Top

Published in:

01-10-2007 | ORIGINAL PAPER

Hepatitis C Hypervariable Region 1: Association of Reduced Selection Pressure in African Americans with Treatment Failure

Authors: Vicki M. Park, Barbara C. Mason, Julia Krushkal, Rongling Li, Caroline Riely, Jaquelyn Fleckenstein

Published in: Digestive Diseases and Sciences | Issue 10/2007

Abstract

In a prospective therapeutic trial, features of the hepatitis C quasispecies were investigated as possible markers of therapeutic response. Individuals chronically infected with hepatitis C genotype 1 received antiviral therapy consisting of α-interferon plus ribavirin. The study targeted the most rapidly evolving segment of the viral genome, hypervariable region 1 within the envelope-2 gene. Among individuals failing to clear virus in response to therapy, significant differences were observed between quasispecies of African-American and Caucasian subjects. While distance measures for synonymous substitutions were similar between racial subgroups, measures of distance at the amino acid level (nonsynonymous substitutions) varied significantly. Taken together, the observed patterns of variability corresponded to reduced host selection pressure against hypervariable region 1 in African-American nonresponders. Reduced selection pressure was present at baseline and persisted through treatment and follow-up, suggesting population stratification of host factors that influence selection pressure on hepatitis C virus.

Kim WR (2002) The burden of hepatitis C in the United States. Hepatology 36:S30–S34PubMedCrossRef

Simmonds P (1995) Variability of hepatitis C virus. Hepatology 21:570–583PubMed

Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, Netesov S, Nishioka K, Shini T, Simmonds P, Smith D, Stuyver L, Weiner A (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143:2493–2503PubMedCrossRef

Ina Y, Mizokami M, Ohba K, Gojobori T (1994) Reduction of synonymous substitutions in the core protein gene of hepatitis C virus. J Mol Evol 38:50–56PubMedCrossRef

McAllister J, Casino C, Davidson F, Power J, Lawlor E, Yap PL, Simmonds P, Smith DB (1998) Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol 72:4893–4905PubMed

Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Remire J, Soussy CJ, Dhumeaux D (1998) Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 54:256–264PubMedCrossRef

Sheridan I, Pybus OG, Holmes EC, Klenerman P (2004) High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 78:3447–3454PubMedCrossRef

Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, Koziel MJ, Sherman KE (2005) HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 105:533–541PubMedCrossRef

Tagariello G, Gerotto M, Pontisso P, Belvini D, Salviato R, Radossi P, Alberti A (2004) Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia. Haemophilia 10:81–86PubMedCrossRef

10.

Zehender G, De Maddalena C, Bernini F, Ebranati E, Monti G, Pioltelli P, Galli M (2005) Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J Virol 79:9145–9156PubMedCrossRef

11.

Ray SC, Mao Q, Lanford RE, Bassett S, Laeyendecker O, Wang YM, Thomas DL (2000) Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol 74:3058–3066PubMedCrossRef

12.

Solmone M, Girardi E, Lalle E, Abbate I, D’Arminio Monforte A, Cozzi-Lepri A, Alessandrini A, Piscopo R, Ebo F, Cosco L, Antonucci G, Ippolito G, Capobianchi MR (2006) Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy. Antivir Ther 11:87–94PubMed

13.

Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93:15394–15399PubMedCrossRef

14.

Frasca L, Scotta C, Del Porto P, Nicosia A, Pasquazzi C, Versace I, Masci AM, Racioppi L, Piccolella E (2003) Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. Hepatology 38:653–663PubMedCrossRef

15.

Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset F-L (2003) Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278:41624–41630PubMedCrossRef

16.

Crotta S, Stilla A, Wack A, D’Andrea A, Nuti S, D’Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195:35–41PubMedCrossRef

17.

Tseng CT, Klimpel GR (2002) Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 195:43–49PubMedCrossRef

18.

Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL (2005) An Interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79:8217–8229PubMedCrossRef

19.

Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T (1997) Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 26:6–13PubMedCrossRef

20.

Ueda E, Enomoto N, Sakamoto N, Hamano K, Sato C, Izumi N, Watanabe M (2004) Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol Res 29:89–96PubMedCrossRef

21.

Alfonso V, Mbayed VA, Sookoian S, Campos RH (2005) Intra-host evolutionary dynamics of hepatitis C virus E2 in treated patients. J Gen Virol 86:2781–2786PubMedCrossRef

22.

Sandres K, Dubois M, Pasquier C, Payen JL, Alric L, Duffaut M, Vinel JP, Pascal JP, Puel J, Izopet J (2000) Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol 74:661–668PubMedCrossRef

23.

Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M, Guilera M, Costa J, Jimenez de Anta MT, Sanchez-Tapias JM, Rodes J, Saiz JC (1999) Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. Hepatology 29:897–903PubMedCrossRef

24.

Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ (2005) Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 41:617– 625PubMedCrossRef

25.

Allain JP, Dong Y, Vandamme AM, Moulton V, Salemi M (2000) Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J Virol 74:2541–2549PubMedCrossRef

26.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982PubMedCrossRef

27.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965PubMedCrossRef

28.

Pawlotsky JM (2003) Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 7:45–66PubMedCrossRef

29.

Farci P, Purcell RH (2000) Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 20:103–126PubMed

30.

Boulestin A, Kamar N, Sandres-Saune K, Legrand-Abravanel F, Alric L, Vinel JP, Rostaing L, Izopet J (2006) Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J Med Virol 78:365–371PubMedCrossRef

31.

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485–1492PubMedCrossRef

32.

Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426–1432PubMedCrossRef

33.

Fleckenstein J (2004) Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 6:66–70PubMedCrossRef

34.

Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39:1702– 1708PubMedCrossRef

35.

Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350:2265– 2271PubMedCrossRef

36.

Zeuzem S (2004) Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140:370–381PubMed

37.

Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ (2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37:1343–1350PubMedCrossRef

38.

Keenan ED, Rouster SD, Shire NJ, Horn PS, Sherman KE (2004) Complexity and diversity of hepatitis C virus RNA in African Americans and whites: analysis of the envelope-coding domain. J Infect Dis 190:511–514PubMedCrossRef

39.

Layden-Almer JE, Kuiken C, Ribeiro RM, Kunstman KJ, Perelson AS, Layden TJ, Wolinsky SM (2005) Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 192:1078–1087PubMedCrossRef

40.

NIH (2002) NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci State 19:1–46

41.

Qiu P, Cai XY, Wang L, Greene JR, Malcolm B (2002) Hepatitis C virus whole genome position weight matrix and robust primer design. BMC Microbiol 2:29PubMedCrossRef

42.

Yao E, Tavis JE (2005) A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J 2:88PubMedCrossRef

43.

Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT (1996) Adaptive evolution of human immunodeficiency virus–type 1 during the natural course of infection. Science 272:537–542PubMedCrossRef

44.

Kumar S, Tamura K, Nei M (2004) MEGA3: integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5:150–163PubMedCrossRef

45.

Nei M, Kumar S (2000) Molecular evolution and phylogenetics. Oxford University Press, New York

46.

Babik JM, Holodniy M (2003) Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J Virol 77:1940–1950PubMedCrossRef

47.

Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH (2002) Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99:3081–3086PubMedCrossRef

48.

Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL (1999) Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 73:2938–2946PubMed

49.

Durante Mangoni E, Forton DM, Ruggiero G, Karayiannis P (2003) Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations. J Med Virol 70:62–73PubMedCrossRef

50.

Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM (2005) Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 79:3071–3083PubMedCrossRef

51.

Gaudy C, Moreau A, Veillon P, Temoin S, Lunel F, Goudeau A (2003) Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome. J Clin Microbiol 41:3615–3622PubMedCrossRef

52.

Rodrigo AG, Mullins JI (1996) Human immunodeficiency virus type 1 molecular evolution and the measure of selection. AIDS Res Hum Retroviruses 12:1681–1685PubMedCrossRef

53.

Pawlotsky JM, Germanidis G, Frainais PO, Bouvier M, Soulier A, Pellerin M, Dhumeaux D (1999) Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 73:6490–6499PubMed

54.

Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT (2004) Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis 189:1472–1481PubMedCrossRef

55.

Brown RJ, Juttla VS, Tarr AW, Finnis R, Irving WL, Hemsley S, Flower DR, Borrow P, Ball JK (2005) Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol 86:1931–1942PubMedCrossRef

56.

Boulestin A, Sandres-Saune K, Payen JL, Alric L, Dubois M, Pasquier C, Vinel JP, Pascal JP, Puel J, Izopet J (2002) Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon–alpha. J Med Virol 68:221–228PubMedCrossRef

57.

Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75:5703– 5710PubMedCrossRef

58.

Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, Chang KM (2003) Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 37:590–599PubMedCrossRef

59.

Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU (2002) First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 9:340–345PubMedCrossRef

60.

Pawlotsky JM (2000) Hepatitis C virus resistance to antiviral therapy. Hepatology 32:889–896PubMedCrossRef

Title: Hepatitis C Hypervariable Region 1: Association of Reduced Selection Pressure in African Americans with Treatment Failure
Authors: Vicki M. Park
Barbara C. Mason
Julia Krushkal
Rongling Li
Caroline Riely
Jaquelyn Fleckenstein
Publication date: 01-10-2007
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 10/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9726-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2007

Hepatolithiasis and Cholangiocarcinoma in Cystic Fibrosis: A Case Series and Review of the Literature

Synthetic Serine Protease Inhibitor, Gabexate Mesilate, Prevents Nuclear Factor-κB Activation and Increases TNF-α-Mediated Apoptosis in Human Pancreatic Cancer Cells

Liver Transplantation Using Hepatitis B Core Antibody−Positive Grafts: Review and University of Tokyo Experience

Drug-Induced Liver Injury: Review Article

Intraductal Papillary Cholangiocarcinoma Associated With von Meyenberg Complexes: A Case Report

Helicobacter pylori Infection and Severity of Reflux-Induced Esophageal Disease in a Cohort of Patients with Columnar-Lined Esophagus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials